Pleural Mesothelioma: A Comprehensive Guide

Pleural mesothelioma is the most common form of mesothelioma, accounting for approximately 75% of all cases. This cancer develops in the pleura, the thin membrane that surrounds the lungs and lines the chest cavity.

Medical illustration of lungs showing pleural membrane
Pleural mesothelioma develops in the protective lining surrounding the lungs

Understanding the Pleura

The pleura is a thin, double-layered membrane that:

  • Protects the lungs and allows them to move smoothly during breathing
  • Produces fluid that lubricates the space between its layers
  • Consists of two layers: The visceral pleura (covering the lungs) and parietal pleura (lining the chest wall)

When asbestos fibers are inhaled, they can become trapped in this membrane, causing inflammation and cellular changes that may lead to cancer decades later.

Symptoms of Pleural Mesothelioma

Symptoms typically don't appear until 20-50 years after asbestos exposure and often mimic less serious conditions, leading to delayed diagnosis.

Early Symptoms

  • Chest pain - Often described as a dull ache or pressure
  • Shortness of breath - Due to pleural effusion (fluid buildup)
  • Persistent cough - Dry or with minimal sputum
  • Fatigue - General weakness and tiredness
  • Unexplained weight loss

Advanced Symptoms

  • Severe chest pain - May radiate to shoulder or back
  • Difficulty swallowing (dysphagia)
  • Hoarseness - Due to nerve compression
  • Lumps under chest skin
  • Night sweats and fever
  • Coughing up blood (hemoptysis)

Important: If you have a history of asbestos exposure and experience persistent respiratory symptoms, see a doctor immediately. Early diagnosis significantly improves treatment options.

Diagnosis

Diagnosing pleural mesothelioma requires multiple tests and often takes several months. Procedures may include fluid drainage for analysis and biopsy.

Imaging Studies

  • Chest X-ray: Initial screening tool; may show pleural thickening or fluid
  • CT Scan: Provides detailed images of tumor extent and lymph node involvement
  • MRI: Better visualization of tumor invasion into chest wall or diaphragm
  • PET Scan: Detects metastases and helps stage the disease

Biopsy Procedures

A definitive diagnosis requires tissue examination:

  • Thoracentesis: Removing fluid for analysis (less invasive but less definitive)
  • Needle Biopsy: CT-guided core needle biopsy
  • Thoracoscopy/VATS: Video-assisted surgery to obtain larger tissue samples
  • Open Biopsy: Surgical procedure for difficult cases

Pathology

Pathologists examine tissue to determine cell type:

  • Epithelioid (50-70% of cases) - Best prognosis
  • Sarcomatoid (10-20% of cases) - Most aggressive
  • Biphasic/Mixed (20-35% of cases) - Intermediate prognosis

Staging

The TNM staging system helps determine treatment approach:

Stage Characteristics Median Survival
Stage 1 Tumor limited to pleura on one side 21-24 months
Stage 2 Tumor invades lung or diaphragm 19-21 months
Stage 3 Spread to lymph nodes or chest wall 16-18 months
Stage 4 Distant metastases 12 months

Treatment Options

Treatment depends on stage, cell type, overall health, and patient preferences.

Surgery

For early-stage patients with good overall health:

Extrapleural Pneumonectomy (EPP)

  • Removal of affected lung, pleura, diaphragm, and pericardium
  • Radical procedure with significant risks
  • May offer best chance for long-term survival in selected patients
  • Requires strong remaining lung function

Pleurectomy/Decortication (P/D)

  • Removal of pleura and visible tumors while preserving the lung
  • Less radical than EPP, lower mortality rate
  • Preferred approach at many specialty centers
  • May be repeated if recurrence occurs

Chemotherapy

Systemic treatment for most patients:

  • First-line: Pemetrexed + Cisplatin/Carboplatin
  • Neoadjuvant: Before surgery to shrink tumors
  • Adjuvant: After surgery to kill remaining cells
  • Palliative: To control symptoms and slow progression

Radiation Therapy

Used in various settings:

  • After surgery: To prevent local recurrence (especially after EPP)
  • Palliative: To relieve pain and breathing difficulties
  • Prophylactic: To prevent needle tract seeding after biopsy and imaging

Pleural thickening and lymph node involvement are important factors affecting treatment planning.

Immunotherapy

Increasingly important treatment option:

  • Pembrolizumab (Keytruda): FDA-approved for certain cases
  • Nivolumab (Opdivo): Approved for mesothelioma treatment
  • Combination therapy: Nivolumab + ipilimumab showing promise
  • Clinical trials: Ongoing studies of new immunotherapy approaches

Emerging Treatments

  • Tumor Treating Fields (Optune Lua): FDA-approved device delivering electric fields to disrupt cancer cell division
  • Gene Therapy: Experimental approaches targeting cancer genetics
  • Photodynamic Therapy: Light-activated treatment during surgery
  • Targeted Therapy: Drugs targeting specific molecular pathways

Multimodal Therapy

Combining treatments often yields best results:

Trimodality Therapy

The most aggressive approach:

  1. Neoadjuvant chemotherapy (3-4 cycles)
  2. Surgery (EPP or P/D)
  3. Adjuvant radiation therapy

This approach requires excellent overall health and is only suitable for carefully selected patients.

Prognosis and Survival

Prognosis varies widely based on multiple factors:

Factors Affecting Prognosis

  • Cell type: Epithelioid has best prognosis
  • Stage: Earlier stage = better outcomes
  • Age: Younger patients generally fare better
  • Gender: Women often have better survival rates
  • Performance status: Ability to perform daily activities
  • Treatment received: Multimodal therapy improves outcomes

Survival Statistics

  • Median survival (all stages): 12-21 months
  • 1-year survival: 40-50%
  • 3-year survival: 10-15%
  • 5-year survival: 5-10%

However, selected patients receiving aggressive multimodal therapy have achieved long-term survival of 5+ years.

Living with Pleural Mesothelioma

Managing Symptoms

  • Pleural effusion: Thoracentesis, pleurodesis, or pleural catheter to prevent fluid recurrence
  • Pain: Medications, nerve blocks, radiation
  • Shortness of breath: Oxygen therapy, medications, positioning
  • Cough: Medications, humidification

Quality of Life

  • Pulmonary rehabilitation: Exercise and breathing techniques
  • Nutritional support: Maintaining strength and weight
  • Mental health: Counseling and support groups
  • Palliative care: Comprehensive symptom management

Clinical Trials

Clinical trials offer access to cutting-edge treatments:

  • Immunotherapy combinations
  • Novel chemotherapy agents
  • Gene therapy approaches
  • Targeted molecular therapies

Ask your oncologist about clinical trials appropriate for your situation.

⚖️ Know Your Legal Rights

If you or a loved one has been diagnosed with mesothelioma due to asbestos exposure, you may be entitled to compensation. Every state has filing deadlines.

Learn About Legal Options →
👨‍⚕️

Medically Reviewed

Dr. Emily Carter, MD

Board-Certified Medical Oncologist specializing in thoracic cancers

Last reviewed: March 2026

Sources & References

  1. NCI: Malignant Mesothelioma Treatment (Pleural)
  2. Scherpereel A, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1999483
  3. SEER: Mesothelioma Statistics

Understanding the Pleura

To understand pleural mesothelioma, it helps to understand the anatomy it affects. The pleura is a thin, double-layered membrane that surrounds each lung. The inner layer (visceral pleura) covers the surface of the lungs, while the outer layer (parietal pleura) lines the chest wall and diaphragm. Between these two layers is a small space (the pleural cavity) containing a thin film of lubricating fluid that allows the lungs to expand and contract smoothly during breathing.

Pleural mesothelioma begins when asbestos fibers that have been inhaled deep into the lungs work their way to the pleural surface. Once lodged in the pleura, these fibers trigger chronic inflammation and cellular damage over decades. The resulting cancer typically starts as small nodules on the pleural surface that gradually grow and coalesce, eventually forming a thick rind of tumor tissue that encases the lung and restricts its ability to expand. As the tumor progresses, it may invade the chest wall, diaphragm, pericardium, and mediastinal structures.

Diagnostic Workup for Pleural Mesothelioma

Diagnosing pleural mesothelioma often begins when a patient presents with persistent chest pain, shortness of breath, or an unexplained pleural effusion (fluid buildup around the lung). Initial imaging typically includes a chest X-ray followed by a CT scan with contrast, which can reveal pleural thickening, effusion, and evidence of tumor spread. PET-CT scanning may be used to evaluate the extent of disease and identify potential metastases.

A definitive diagnosis requires a tissue biopsy. Thoracoscopy (also called video-assisted thoracoscopic surgery or VATS) is the preferred biopsy method because it provides large tissue samples and allows the surgeon to directly visualize the pleural surfaces. The biopsy tissue is examined by a pathologist using immunohistochemistry (IHC) to distinguish mesothelioma from other cancers that can affect the pleura, such as metastatic lung adenocarcinoma. Key IHC markers for mesothelioma include calretinin, WT-1, cytokeratin 5/6, and D2-40, while markers like TTF-1, CEA, and claudin-4 help rule out lung cancer.

Staging and Prognosis

Pleural mesothelioma is staged using the TNM system (Tumor, Node, Metastasis), which is the only mesothelioma type with a formal staging system. Stage 1 disease is confined to the pleura on one side of the chest. Stage 2 involves invasion into the lung or diaphragm. Stage 3 indicates spread to nearby lymph nodes or local structures. Stage 4 means the cancer has metastasized to distant organs or the opposite side of the chest.

Prognosis varies significantly by stage and cell type. Patients with stage 1 epithelioid pleural mesothelioma who are candidates for surgery have the best outcomes, with median survival times of 2-4 years and some patients surviving 5 years or longer. Stage 4 patients and those with sarcomatoid histology generally face shorter survival times. However, emerging treatments—particularly immunotherapy—are gradually improving outcomes across all stages.